154 related articles for article (PubMed ID: 37371624)
21. Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.
Auma AWN; Kowal C; Shive CL; Lange A; Damjanovska S; Zebrowski E; Reyes E; Calabrese L; Kostadinova L; Falck-Ytter Y; Mattar M; Anthony DD
PLoS One; 2022; 17(4):e0267512. PubMed ID: 35482664
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
Chadha N; Turner A; Sterling RK
J Viral Hepat; 2023 Jan; 30(1):73-78. PubMed ID: 36301045
[TBL] [Abstract][Full Text] [Related]
23. Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response.
Gavril OI; Arhire LI; Gavrilescu O; Dranga M; Barboi O; Gavril RS; Popescu R; Cijevschi Prelipcean C; Trifan AV; Mihai C
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833371
[No Abstract] [Full Text] [Related]
24. Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients.
Rout G; Kedia S; Nayak B; Yadav R; Das P; Acharya SK; Gunjan D; Singh V; Mahanta M; Gupta S; Aggarwal S; Shalimar
J Clin Exp Hepatol; 2019; 9(1):13-21. PubMed ID: 30765934
[TBL] [Abstract][Full Text] [Related]
25. Direct-Acting Antiviral Treatment of HCV Infection Does Not Resolve the Dysfunction of Circulating CD8
Vranjkovic A; Deonarine F; Kaka S; Angel JB; Cooper CL; Crawley AM
Front Immunol; 2019; 10():1926. PubMed ID: 31456810
[TBL] [Abstract][Full Text] [Related]
26. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
[TBL] [Abstract][Full Text] [Related]
27. Effect of treatment with direct acting antivirals on body mass index and hepatic steatosis in chronic hepatitis C.
Shousha HI; Abdelaziz RA; Azab SM; Khairy M; Afifi SA; Mehrez MI; Eshra MA; Abdelrahim AY
J Med Virol; 2018 Jun; 90(6):1099-1105. PubMed ID: 29469217
[TBL] [Abstract][Full Text] [Related]
28. Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection.
Kuriry H; Casey J; Krassenburg L; La D; Kuczynski M; Shah H; Janssen HLA; Hansen BE; Feld JJ
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2398-2406.e1. PubMed ID: 32629131
[TBL] [Abstract][Full Text] [Related]
29. Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment.
Khera T; Madsen LW; Du Y; Lillevang ST; Christensen PB; Wedemeyer H
J Viral Hepat; 2022 Jun; 29(6):447-454. PubMed ID: 35122346
[TBL] [Abstract][Full Text] [Related]
30. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
[TBL] [Abstract][Full Text] [Related]
31. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents.
Terziroli Beretta-Piccoli B; Di Bartolomeo C; Deleonardi G; Grondona AG; Silvestri T; Tesei C; Melidona L; Cerny A; Mertens J; Semmo N; Semela D; Moradpour D; Mieli-Vergani G; Vergani D; Muratori L;
J Autoimmun; 2019 Aug; 102():89-95. PubMed ID: 31047768
[TBL] [Abstract][Full Text] [Related]
32. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice.
Yen YH; Chen JF; Wu CK; Lin MT; Chang KC; Tseng PL; Tsai MC; Lin JT; Hu TH
J Formos Med Assoc; 2017 Nov; 116(11):852-861. PubMed ID: 28888355
[TBL] [Abstract][Full Text] [Related]
33. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.
Seto WK; Hui RWH; Mak LY; Fung J; Cheung KS; Liu KSH; Wong DK; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):575-583.e2. PubMed ID: 28970146
[TBL] [Abstract][Full Text] [Related]
34. Peripheral PD-1
Romani S; Stafford K; Nelson A; Bagchi S; Kottilil S; Poonia B
Front Immunol; 2019; 10():1470. PubMed ID: 31316516
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.
Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA;
J Gastroenterol Hepatol; 2013 Nov; 28(11):1770-81. PubMed ID: 23663030
[TBL] [Abstract][Full Text] [Related]
36. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
Wang CC; Tseng KC; Tzeng IS; Kao JH
J Formos Med Assoc; 2021 Mar; 120(3):965-973. PubMed ID: 33129621
[TBL] [Abstract][Full Text] [Related]
37. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center.
Sung JC; Bosh C; Wyatt B; Miller M; Harty A; Del Bello D; Knight S; Dieterich DT; Perumalswami PV; Branch AD
J Viral Hepat; 2020 Apr; 27(4):350-359. PubMed ID: 31742821
[TBL] [Abstract][Full Text] [Related]
39. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
[TBL] [Abstract][Full Text] [Related]
40. Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy.
Kostadinova L; Shive CL; Zebrowski E; Fuller B; Rife K; Hirsch A; Compan A; Moreland A; Falck-Ytter Y; Popkin DL; Anthony DD
Pathog Immun; 2018 Sep; 3(1):149-163. PubMed ID: 30370392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
